Science & Technology
Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R44CA271994-02
Award Ceiling
$2.0M
Award Floor
$2.0M
Close Date
Dec 31, 2024
Total Funding
$2.0M
Expected Awards
1
Posted Date
May 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-4R44CA271994-02
Description
SBIR Phase Phase II award: "Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas" awarded to MODIFI BIOSCIENCES INC in New Haven, Connecticut. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,000,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.